Current Report Filing (8-k)
June 20 2019 - 5:05PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June
18, 2019
SCPHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-38293
|
|
46-5184075
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
2400 District Avenue, Suite 310
Burlington, Massachusetts
|
|
01803
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617)
517-0730
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, par value $0.0001
|
|
SCPH
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
The 2019 Annual Meeting of Stockholders (the Annual Meeting) of scPharmaceuticals Inc. (the Company) was held on June 18, 2019.
Proxies were solicited pursuant to the Companys proxy statement filed on April 30, 2019, with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended.
The number of shares of the Companys common stock, $0.0001 par value per share (Common Stock), entitled to vote at the Annual Meeting was
18,580,430. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 15,657,729, representing 84.27% of the total number of shares of Common Stock entitled to vote at the Annual Meeting. Each share of
Common Stock was entitled to one vote with respect to matters submitted to the Companys stockholders at the Annual Meeting.
At the Annual Meeting,
the Companys stockholders were asked (i) to elect three Class II directors to the Companys Board of Directors, each to hold office until the 2022 annual meeting of stockholders and until his or her successor is duly elected and
qualified, or until his or her earlier resignation or removal and (ii) to ratify the appointment of RSM US LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2019.
The voting results reported below are final.
Proposal 1
Election of Directors
Mette Kirstine Agger, Mason Freeman M.D., and Minnie Baylor-Henry were duly elected to the Companys Board of
Directors as Class II directors. The results of the election were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NOMINEE
|
|
FOR
|
|
|
% FOR
|
|
|
|
|
WITHHELD
|
|
|
%
WITHHELD
|
|
|
|
|
BROKER
NON-
VOTES
|
|
Mette Kirstine Agger
|
|
|
13,313,661
|
|
|
|
98.83
|
|
|
%
|
|
|
157,514
|
|
|
|
1.17
|
|
|
%
|
|
|
2,186,554
|
|
Mason Freeman, M.D.
|
|
|
13,333,610
|
|
|
|
98.98
|
|
|
%
|
|
|
137,565
|
|
|
|
1.02
|
|
|
%
|
|
|
2,186,554
|
|
Minnie Baylor-Henry
|
|
|
13,406,074
|
|
|
|
99.52
|
|
|
%
|
|
|
65,101
|
|
|
|
0.48
|
|
|
%
|
|
|
2,186,554
|
|
Proposal 2 Ratify the Appointment of Independent Registered Public Accounting Firm
The appointment of RSM US LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2019 was
ratified. The results of the ratification were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FOR
|
|
|
|
|
AGAINST
|
|
|
|
|
ABSTAIN
|
|
|
|
NUMBER
|
|
|
15,616,814
|
|
|
|
|
|
40,802
|
|
|
|
|
|
113
|
|
|
|
PERCENTAGE OF VOTED
|
|
|
99.73
|
|
|
%
|
|
|
0.26
|
|
|
%
|
|
|
0.00
|
|
|
%
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SCPHARMACEUTICALS INC.
|
|
|
|
|
Date: June 20, 2019
|
|
|
|
By:
|
|
/s/ John H. Tucker
|
|
|
|
|
Name:
|
|
John H. Tucker
|
|
|
|
|
Title:
|
|
President, Chief Executive Officer, Principal
Executive Officer and Principal Financial Officer
|
scPharmaceuticals (NASDAQ:SCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
scPharmaceuticals (NASDAQ:SCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024